SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 13, 2026

RCKT

ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed3mo ago
Insider cluster: 2 insiders, $145K total
Actionable Insight • Neutral

The insider sales are routine in size and timing (post-earnings blackout window opening). No bearish read-through, the COO's sale is likely diversification after the stock's recent volatility. Monitor for any larger insider sales or 10b5-1 plan adoption, but this cluster alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonimmediate

RP-A501

● Neutral Named in this insider cluster
Impact
Phase
Phase 2 (pivotal/registrational)
Time to market
If the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.
Next catalyst
None dated

What to watchWatch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.47
T+0 close · Aug 13, 2026 · via day close
Latest settled
−27.09%
T+60 · $2.53
Vs SPY
−24.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $3.47entry
  2. T+1 · 3mo ago −2.02%α −1.54% · $3.40
  3. T+5 · 3mo ago +1.15%α +2.52% · $3.51
  4. T+20 · 2mo ago −1.15%α +0.84% · $3.43
  5. T+60 · 8d ago −27.09%α −24.04% · $2.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two insiders at Rocket Pharmaceuticals, including the COO, sold a combined $145K in open-market sales on August 11, 2026, just three days after the company reported a Q2 2026 GAAP net income of $123.2M driven by a $178.2M PRV sale. The sales are small relative to the $374M market cap (0.04%), and the cluster is not amplified per academic literature since insider sales are weak predictors. The trades likely reflect routine portfolio diversification following the positive earnings catalyst, not a bearish signal on fundamentals.

Key Financial Metrics

Direction
selling
Total Value
$144.7K
Insiders
2

Key Facts

  • COO Christopher Stevens sold 36,658 shares for $128K at $3.50/share on Aug 11, 2026
  • Sarbani Chaudhuri sold 4,701 shares for $16K at $3.50/share on Aug 11, 2026
  • Total insider sales of $145K represent 0.04% of RCKT's $374M market cap
  • Sales occurred 3 days after Q2 2026 earnings release showing $123.2M net income and $283.7M cash runway into Q2 2028

Financial Impact

Insider sales of $145K are immaterial relative to $374M market cap (0.04%)

insider ownership

Risk Factors

  • Insider sales could accelerate if stock rallies further
  • No C-suite buys to offset the selling signal
  • Small sample size (2 trades) limits statistical significance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RCKT-1786691343806

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026